Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled PRS-220 in Healthy Subjects
NCT05473533Phase 1Completed
- Sponsor
- Pieris Pharmaceuticals
- Start
- Oct 2022
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Placebo with PRS-220 (2 arms). Primary endpoints: Adverse Events, Serious Adverse Events and 10 more. Started Oct 2022; status: completed.
02
Drugs
PRS-220
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05473533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05473533.